Eohilia denied as non-formulary by Aetna?

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Eohilia as Non-Formulary

Eohilia (budesonide oral suspension) may sit in a non-preferred tier or be excluded from Aetna's drug formulary for a given plan year. A non-formulary denial does not mean coverage is impossible — it means you must obtain a formulary exception by demonstrating that no covered formulary alternative is clinically appropriate for your specific situation.

Non-formulary exception requests are a recognized and frequently successful appeal pathway, particularly for conditions — like eosinophilic esophagitis — where a formulary alternative may not be therapeutically equivalent.

## Your Federal Appeal Rights

• Formulary exception / internal appeal: Under ACA and ERISA rules, plans must have a process for requesting exceptions to formulary placement. Your prescriber can submit an exception request, and you may file a simultaneous internal appeal.
• External review (ACA §2719): If the exception is denied and you exhaust internal appeals, you may request binding independent external review. The external reviewer evaluates whether denying coverage is consistent with generally accepted standards of care.
• Expedited review: Available when delay would seriously jeopardize your health — reviewer must respond within 72 hours.
• Four-month window: Most plans allow external review requests within approximately four months of a final internal denial. Check your denial letter for the exact deadline.

## The Concrete Appeal Process

1. Ask Aetna for the plan's formulary exception form and the list of formulary alternatives in the same therapeutic category. 2. Have your prescriber document why each formulary alternative is clinically inappropriate for you (not just less preferred — actually contraindicated, previously failed, or not indicated for your specific diagnosis). 3. Submit an exception request supported by the medical-necessity documentation below. 4. If the exception is denied, file a formal internal appeal; if that is denied, request external review.

## Documentation to Gather

• Diagnosis records: Specialist notes and pathology/endoscopy reports confirming the EoE diagnosis.
• Formulary-alternative trial history: Dates, doses trialed, and documented clinical outcomes or reasons why each covered alternative was not appropriate, insufficient, or not tolerated.
• Clinical severity documentation: Current symptom records, recent endoscopy findings, and any validated assessment tool scores recorded in the chart.
• Prescriber exception letter: A detailed letter from the treating specialist explaining why Eohilia — as opposed to any formulary alternative — is the medically necessary drug for this patient, citing the FDA-approved indication and applicable professional society guidelines for EoE management (reference the organization, not specific numbers).

## Criteria-Mapping Strategy

Aetna's formulary exception standard typically requires proof that no formulary drug is clinically equivalent for your condition. Build a side-by-side table: formulary alternative vs. reason it is inappropriate or was trialed and failed. Pair this with a clear narrative from your specialist. When reviewers see a structured, criterion-by-criterion response that leaves no coverage gap, exception approvals become far more likely.